Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activation-induced cytidine deaminase (AID) is a DNA/RNA-editing enzyme encoded by the *AICDA* gene and is the evolutionary founding member of the APOBEC protein family. It is responsible for cytidine-to-uracil deamination in single-stranded DNA, which is critical for somatic hypermutation and class switch recombination in B cells—processes that diversify antibody specificity and enable adaptive immunity. AID also influences epigenetic gene regulation by DNA demethylation and has a tightly regulated expression and activity to prevent mutagenesis and carcinogenesis. Mutations or dysregulation of AID cause clinical conditions such as Hyper-IgM Syndrome type 2 immunodeficiency and contribute to the development of lymphomas and possibly other malignancies. No approved drugs currently target AID directly; therapeutic interest focuses on its pathogenic overactivity in cancer and immunodeficiency.
Not applicable; currently, drugs targeting AID are not in established clinical use. Theoretical approaches could involve inhibition or modulation of its deaminase activity or regulation of its expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activation-induced cytidine deaminase (AID).